Viking Announces Phase 3 Trials for Oral Obesity Treatment
Viking Therapeutics reported $960 million in cash and initiated the Phase 3 SUNRISE study for its oral obesity treatment, raising hopes for a differentiated therapy option.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed